Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04620551|
Recruitment Status : Recruiting
First Posted : November 9, 2020
Last Update Posted : January 14, 2021
|Condition or disease|
|Parkinson Disease Sleep Fragmentation|
Although STN-DBS is routinely used to treat PD motor symptoms, several studies have reported that STN-DBS also provides benefit for sleep dysregulation through normalization of sleep architecture. In our previous work, using local field potentials (LFP) recorded from STN DBS electrodes implanted for the treatment of PD, unique spectral patterns in STN oscillatory activity were identified that correlated with distinct sleep cycles, offering insight into sleep dysregulation. These findings were used to construct an Artificial Neural Network (ANN) that can accurately predict sleep stage. Building on this work with the use of new DBS battery technology that allows exploration of potential biomarkers and prototyping of closed-loop algorithms, the investigators will test the hypothesis that STN-a highly interconnected node within the basal ganglia- contributes to the regulation and disruption of human sleep behavior and can be manipulated for therapeutic advantage.
This is the first part, Aim 1, of a two-part study. Investigators will enroll 20 subjects for Aim 1 of this study and 20 subjects for Aim 2, with 10 subjects enrolled at each clinical site for each aim (University of Nebraska Medical Center and Stanford University Medical Campus). In Aim 1, subjects will undergo standard-of-care STN DBS lead implantation surgery for the treatment of PD. They will return 3 weeks later to the in-patient Sleep Lab for 3 nights of STN LFP recordings with concurrent PSG, EMG, EOG, actigraphy, and video-EEG. The first two nights of recording will be used to establish a physiological sleep baseline for each patient. The third night of recording will involve sub-clinical thresholds of stimulation in all subjects, in an effort to favorably alter sleep-stage duration, so that NREM and REM-3 are prolonged. As a secondary outcome, subjects will be asked to complete a sleep questionnaire for all three nights, sleep during which stimulation occurred will be compared to the preceding two nights. Data collected during all three nights of recordings will be used to predict sleep stage identity from the LFPs recorded within STN, with the ground truth for each sleep stage provided by sleep-expert evaluated PSG. These data will also be used to identify the optimal sub-clinical threshold current amplitude and sleep-stage timing for adaptive stimulation to improve sleep. The stimulation algorithm developed in Aim 1 will be implemented in the second part of the study, Aim 2, to provide adaptive stimulation to subjects during nighttime sleep, over the course of 3 weeks of in-home sleep.
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease: An Investigation of STN LFP Biomarkers in Sleep Dysregulation and Repair|
|Actual Study Start Date :||October 1, 2020|
|Estimated Primary Completion Date :||October 2025|
|Estimated Study Completion Date :||October 2025|
PD with DBS
Patients with Parkinson's Disease who opt for DBS surgery and consent to participate in the sleep study.
- Sleep stage detection accuracy [ Time Frame: Years 1-2 ]We will measure the accuracy of our artificial neural network to predict sleep stage identity from the local field potentials recorded within the subthalamic nucleus. The ground truth for the sleep stage will be provided by sleep-expert evaluated polysomnography.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04620551
|Contact: Dulce Maroni, PhDfirstname.lastname@example.org|
|Contact: Andrew Schnaubelt, PhDemail@example.com|
|United States, California|
|Standord University Medical Center||Recruiting|
|Stanford, California, United States, 94305|
|Principal Investigator: Casey Halpern, MD|
|Principal Investigator: Clete Kushida, MD, PhD|
|United States, Colorado|
|University of Colorado Denver School of Medicine||Active, not recruiting|
|Aurora, Colorado, United States, 80045|
|United States, Nebraska|
|University of Nebraska Medical Center||Recruiting|
|Omaha, Nebraska, United States, 68198|
|Contact: Dulce Maroni, PhD 402-836-9751 firstname.lastname@example.org|
|Contact: Andrew Schnaubelt, PhD 402.559.4846 email@example.com|
|Principal Investigator: Aviva Abosch, MD, PhD|
|Study Director:||Aviva Abosch, MD, PhD||University of Nebraska|
|Principal Investigator:||Casey Halpern, MD||Stanford University|
|Principal Investigator:||Clete Kushida, MD, PhD||Stanford University|
|Principal Investigator:||John Thompson, PhD||University of Colorado, Denver|